INHIBITION OF PCSK9 AFFECTS SERUM LIPOPROTEIN FUNCTIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引：0
|
作者：
Palumbo, M. [1 ]
Adorni, M. P. [2 ]
Zimetti, F. [1 ]
Pavanello, C. [3 ]
Giammanco, A. [4 ]
Cefalu, A. B. [4 ]
Noto, D. [4 ]
Piro, S. [5 ]
Di Pino, A. [5 ]
Averna, M. [4 ]
Calabresi, L. [3 ]
Bernini, F. [1 ]
Purrello, F. [5 ]
Scicali, R. [5 ]
机构：
[1] Univ Parma, Dept Food & Drug, Parma, Italy
[2] Univ Parma, Dept Med & Surg, Unit Neurosci, Parma, Italy
[3] Univ Milan, Pharmacol & Biomol Sci, Milan, Italy
[4] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy
[5] ARNAS GARIBALDI NESIMA, Dept Med, Catania, Italy
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP222
引用
收藏
页码：E157 / E157
页数：1
相关论文
共 50 条
  • [31] Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
    Huijgen, R.
    Fouchier, S. W.
    Denoun, M.
    Hutten, B. A.
    Vissers, M. N.
    Lambert, G.
    Kastelein, J. J. P.
    JOURNAL OF LIPID RESEARCH, 2012, 53 (05) : 979 - 983
  • [32] A Novel Cause of Familial Hypercholesterolemia: PCSK9 Gene Duplication
    Paquette, Martine
    Baass, Alexis
    CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (10) : 1259 - 1260
  • [33] Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab
    Lambert, Gilles
    Chatelais, Mathias
    Petrides, Francine
    Passard, Maxime
    Thedrez, Aurelie
    Rye, Kerry-Anne
    Schwahn, Uwe
    Gusarova, Viktoria
    Blom, Dirk J.
    Sasiela, William
    Marais, A. David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (21) : 2299 - 2300
  • [34] Familial hypercholesterolemia: functional characterization of new variants in PCSK9
    Rodriguez-Novoa, S.
    Rodriguez-Jimenez, C.
    Sanchez-Nieves, E.
    Carazo-Alvarez, A.
    Arrieta, F.
    Reinares-Garcia, L.
    Martinez-Hernandez, P.
    Canas, R.
    Mostaza, J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1326 - 1326
  • [35] Response to PCSK9 Inhibition in Homozygous Familial Hypercholesterolemia Patients is Variable in Different Regions of the World and According to Age
    Raal, Frederick J.
    Mehta, Vimal
    Kayikcioglu, Meral
    Blom, Dirk J.
    Gupta, Preeti
    Durst, Ronen
    Asprusten, Emil A.
    Turner, Traci
    Bahassi, El Mustapha
    Vest, Jeffrey
    Caldwell, Kate
    CIRCULATION, 2023, 148
  • [36] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [37] Hypercholesterolemia: The role of PCSK9
    Melendez, Quantil M.
    Krishnaji, Sreevidhya T.
    Wooten, Catherine J.
    Lopez, Dayami
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2017, 625 : 39 - 53
  • [38] Targeting PCSK9 for Hypercholesterolemia
    Norata, Giuseppe Danilo
    Tibolla, Gianpaolo
    Catapano, Alberico Luigi
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54, 2014, 54 : 273 - 293
  • [39] Statins, But Not Pcsk9 Inhibitors, Reduce The Adipokine Chemerin In Familial Hypercholesterolemia: Focus On Lipoprotein Subfractions.
    Tan, Lunbo
    Wang, Na
    Zee, Leonie V.
    van Lennep, Jeanine Roeters
    Mulder, Monique T.
    Lu, Xifeng
    Danser, A. H. Jan
    Verdonk, Koen
    HYPERTENSION, 2022, 79
  • [40] Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia
    Papaioannou, Theodore G.
    Alexandraki, Krystallenia I.
    Tousoulis, Dimitrios
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (04) : 542 - 542
12345